Robin Washington, chief operating and financial officer at Salesforce, talks agentic AI and offers career advice.

Gilead Sciences Inc. settled for $202 million over illegal kickbacks for HIV drug prescriptions, following Attorney General ...

Explore the exciting world of Gilead Sciences (NASDAQ: GILD) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends ...

Gilead Sciences (GILD) concluded the recent trading session at $105.93, signifying a -1.18% move from its prior day's close.

Gilead Sciences GILD has outperformed the market over the past 20 years by 3.67% on an annualized basis producing an average annual return of 12.17%. Currently, Gilead Sciences has a market ...

(RTTNews) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate the ...

Gilead Sciences partners with Kymera Therapeutics to develop cancer drugs, with Kymera eligible for up to $750M & royalties. Read more here.

Biotech Kymera suffers Sanofi setback but secures $750M Gilead deal By Nick Paul Taylor Jun 25, 2025 9:31am Kymera Therapeutics Sanofi Gilead Sciences molecular glue ...

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

The FDA approved Gilead Sciences ’ new medicine, lenacapavir, a long-acting antiviral that treats HIV. The agency approved Daiichi Sanyo and AstraZeneca ’s Datroway for patients with previously ...